A phase II study of CPX-351 in adult patients with first-relapse acute myeloid leukemia demonstrated clinical benefit in patients with poor-risk disease as defined by the European Prognostic Index.
As NCI employees and others at HHS were receiving notices of termination, national cancer organizations called on Congress “to restore stability to NIH.”
